Turn Therapeutics Inc.
TTRX
$3.98
$0.102.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 576.25% | 237.68% | 355.56% | 135.83% | -24.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 717.78% | 184.34% | 279.37% | 120.27% | -22.22% |
| Operating Income | -717.78% | -184.34% | -279.37% | -120.27% | 22.22% |
| Income Before Tax | 186.38% | -185.74% | -252.49% | -101.46% | 22.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 186.38% | -185.74% | -252.49% | -101.46% | 22.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 186.38% | -185.74% | -252.49% | -101.46% | 22.59% |
| EBIT | -717.78% | -184.34% | -279.37% | -120.27% | 22.22% |
| EBITDA | -745.36% | -187.47% | -288.33% | -123.59% | 23.67% |
| EPS Basic | 181.67% | -172.40% | -239.10% | -95.92% | 24.05% |
| Normalized Basic EPS | 181.33% | -172.44% | -239.76% | -95.65% | 23.47% |
| EPS Diluted | 181.67% | -172.40% | -239.10% | -95.92% | 24.05% |
| Normalized Diluted EPS | 181.33% | -172.44% | -239.76% | -95.65% | 23.47% |
| Average Basic Shares Outstanding | 5.54% | 4.99% | 3.73% | 2.67% | 1.66% |
| Average Diluted Shares Outstanding | 5.54% | 4.99% | 3.73% | 2.67% | 1.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |